The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease
Open accessAbstract
Objectives Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo. Design Placebo-controlled, randomized, double-blind trial. Setting Outpatient memory clinics at five academic medical centers in the United States. Participants A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26. Intervention Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial. Measurements Mini-Mental State Examination, cognitive subscale of the Alzheimer's Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline. Results A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general. Conclusions Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other RCTs in AD indicated that sertraline and escitalopram had no effect on cognitive function.
“In contrast, other RCTs in AD indicated that another two SSRIs, sertraline and escitalopram, had no effect on cognitive function [49, 50].”
From Antidepressant use and cognitive decline in patients with dementia: a national cohort study (2025) · cites this paper as [50]
The DIADS-2 study indicated that sertraline neither improved nor impaired cognitive function in patients with depression of Alzheimer's disease.
“the DIADS-2 study indicated that another SSRI, sertraline, neither improved nor impaired cognitive function in patients with depression of Alzheimer's disease39.”
From Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial (2014) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation after 18+ years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476908 · Cited by 4,072
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Self-citationSertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250
Self-citationA Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163
Flagged first, then by citations
Research works printed but not linked: 20
- Lee, 2003, Depression in Alzheimer's disease: heterogeneity and related issues, Biol Psychiatry, 54, 353, 10.1016/S0006-3223(03)00543-2 · DOI
- Alexopoulos, 2002, Clinical presentation of the “depression-executive dysfunction syndrome” of late life, Am J Geriatr Psychiatry, 10, 98
- Cui, 2007, Does depression precede or follow executive dysfunction? Outcomes in older primary care patients, Am J Psychiatry, 164, 1221, 10.1176/appi.ajp.2007.06040690 · DOI
- Elderkin-Thompson, 2003, Neuropsychological deficits among patients with late-onset minor and major depression, Arch Clin Neuropsychol, 18, 529, 10.1016/S0887-6177(03)00022-2 · DOI
- Munro, 2004, Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the Depression in Alzheimer's Disease Study (DIADS), Am J Geriatr Psychiatry, 12, 491, 10.1097/00019442-200409000-00007 · DOI
- Olin, 2002, Provisional diagnostic criteria for depression of Alzheimer disease, Am J Geriatr Psychiatry, 10, 125, 10.1097/00019442-200203000-00003 · DOI
- Rosenberg, 2005, Depression of Alzheimer's disease study. Clinical application of operationalized criteria for “Depression of Alzheimer's disease”, Int J Geriatr Psychiatry, 20, 119, 10.1002/gps.1261 · DOI
- Weintraub, 2010, Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes, Am J Geriatr Psychiatry, 18, 332, 10.1097/JGP.0b013e3181cc0333 · DOI
- Martin, 2006, Design of Depression in Alzheimer's Disease Study-2, Am J Geriatr Psychiatry, 14, 920, 10.1097/01.JGP.0000240977.71305.ee · DOI
- Folstein, 1975, “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Schneider, 1997, Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord, 11, S22, 10.1097/00002093-199700112-00004 · DOI
- Wefel, 1999, Neuropsychological functioning in depressed versus nondepressed participants with Alzheimer's disease, Clin Neuropsychol, 13, 249, 10.1076/clin.13.3.249.1746 · DOI
- Finkel, 1999, Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression, Am J Geriatr Psychiatry, 7, 221, 10.1097/00019442-199908000-00006 · DOI
- Furlan, 2001, Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers, Am J Geriatr Psychiatry, 9, 429, 10.1097/00019442-200111000-00012 · DOI
- Bondareff, 2000, Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life, Am J Psychiatry, 157, 729, 10.1176/appi.ajp.157.5.729 · DOI
- Rosen, 1984, A new rating scale for Alzheimer's disease, Am J Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
- Stern, 1994, A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration, Am J Psychiatry, 151, 390, 10.1176/ajp.151.3.390 · DOI · Paper page
- Borkowski, 1967, Word fluency and brain damage, Neuropsychologia, 5, 135, 10.1016/0028-3932(67)90015-2 · DOI
- Livingston, 2007, Antipsychotics and cognitive decline in Alzheimer's disease: the LASER–Alzheimer's disease longitudinal study, J Neurol Neurosurg Psychiatry, 78, 25, 10.1136/jnnp.2006.094342 · DOI
- Lopez, 1999, Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease, Arch Neurol, 56, 1266, 10.1001/archneur.56.10.1266 · DOI
Cited by
Sorted by citations
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Self-citationBartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202
Antidepressant use and cognitive decline in patients with dementia: a national cohort study
Mo, M., Abzhandadze, T., Hoang, M. T., Sacuiu, S., Jurado, P. G., Pereira, J. B., Naia, L., Kele, J., Maioli, S., Xu, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03851-3 · Cited by 45
Metadata
- Authors
- Munro, C. A., Longmire, C. F., Drye, L. T., Martin, B. K., Frangakis, C. E., Meinert, C. L., Mintzer, J. E., Porsteinsson, A. P., Rabins, P. V., Rosenberg, P. B., Schneider, L. S., Weintraub, D., & Lyketsos, C. G.
- Affiliations
- Johns Hopkins University (US)
- Medical University of South Carolina (US)
- University of Rochester Medicine (US)
- University of Southern California (US)
- University of Pennsylvania (US)
- Corresponding author
- Munro, Cynthia A.
- ORCID
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 20
- Issue
- 12
- Pages
- 1036-1044
- ISSN
- 1064-7481 (ISSN-L)
- PMC
- PMC3508666
- OpenAlex
- W2167647325
- Cited by
- 49
- References
- 4
- Citations by year
- 2025: 4 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 4 · 2013: 7 · 2012: 1
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u01mh068014-05, 5u01mh066176-05, 5u01mh066174-05, 5u01mh066177-05, 5u01mh066175-05)
- National Institute on Aging (P50AG005146)
- National Institute of Mental Health (U01 MH068014, U01 MH066174, 1U01MH066175, 1U01MH068014, U01MH066177, 1U01MH066177, 1U01MH066176, U01 MH066175, 1U01MH066174, U01 MH066176, U01MH066136)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- sertraline, Alzheimer's disease, cognitive outcomes, antidepressant treatment, cognitive impairment, depression remission
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Ambulatory Care Facilities, Antidepressive Agents, Cognition, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Treatment Outcome, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
